Although microsatellite-stable (MSS) CRC typically shows a low response rate to PD-1/PD-L1 inhibitors, interventions targeting the bacterial microbiota have been shown to improve treatment efficacy (62). This evidence concerns the gene CD274 and colorectal carcinoma.